ATE350057T1 - Impfstoffzusammesetzung - Google Patents

Impfstoffzusammesetzung

Info

Publication number
ATE350057T1
ATE350057T1 AT01976380T AT01976380T ATE350057T1 AT E350057 T1 ATE350057 T1 AT E350057T1 AT 01976380 T AT01976380 T AT 01976380T AT 01976380 T AT01976380 T AT 01976380T AT E350057 T1 ATE350057 T1 AT E350057T1
Authority
AT
Austria
Prior art keywords
vaccine composition
pharmaceutical composition
composition
antigen
hiv
Prior art date
Application number
AT01976380T
Other languages
English (en)
Inventor
Jean Haensler
Christian Marcel Hurpin
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE350057T1 publication Critical patent/ATE350057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
AT01976380T 2000-10-06 2001-10-08 Impfstoffzusammesetzung ATE350057T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale

Publications (1)

Publication Number Publication Date
ATE350057T1 true ATE350057T1 (de) 2007-01-15

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus

Country Status (12)

Country Link
US (3) US20040038922A1 (de)
EP (2) EP1326635B1 (de)
AT (2) ATE350057T1 (de)
AU (2) AU2001295671A1 (de)
CA (1) CA2424836A1 (de)
CY (1) CY1105943T1 (de)
DE (2) DE60110822T2 (de)
DK (1) DK1326636T3 (de)
ES (2) ES2240526T3 (de)
FR (1) FR2814958B1 (de)
PT (2) PT1326636E (de)
WO (2) WO2002028428A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
WO2001095935A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
CN1604795B (zh) * 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
US20090117132A1 (en) * 2005-07-07 2009-05-07 Pfizer, Inc. Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
CA2363141C (en) * 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
IL148359A0 (en) * 1999-08-27 2002-09-12 Inex Pharmaceuticals Corp Pharmaceutical compositions containing an oligodeoxynucleotide
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
ES2275738T3 (es) 2007-06-16
EP1326636B1 (de) 2007-01-03
ES2240526T3 (es) 2005-10-16
WO2002028428A3 (fr) 2003-02-20
CY1105943T1 (el) 2011-04-06
WO2002028428A2 (fr) 2002-04-11
DK1326636T3 (da) 2007-04-30
US20040038922A1 (en) 2004-02-26
ATE295180T1 (de) 2005-05-15
WO2002028427A2 (fr) 2002-04-11
EP1326635A2 (de) 2003-07-16
PT1326636E (pt) 2007-02-28
AU2001295671A1 (en) 2002-04-15
US20030190326A1 (en) 2003-10-09
PT1326635E (pt) 2005-08-31
CA2424836A1 (en) 2002-04-11
EP1326635B1 (de) 2005-05-11
DE60125797D1 (de) 2007-02-15
DE60125797T2 (de) 2007-12-06
US20050118188A1 (en) 2005-06-02
DE60110822D1 (de) 2005-06-16
FR2814958B1 (fr) 2003-03-07
DE60110822T2 (de) 2006-05-11
WO2002028427A3 (fr) 2003-03-20
EP1326636A2 (de) 2003-07-16
AU2001295673A1 (en) 2002-04-15
FR2814958A1 (fr) 2002-04-12

Similar Documents

Publication Publication Date Title
DK1326636T3 (da) Vaccinesammensætning
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
NO20023829L (no) Proteosom influensavaksine
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
EP1301208A4 (de) Impfstoff
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
BR0211181A (pt) Formulação vacinal
WO2004050692A3 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
NO953311L (no) Anvendelse av anti-helmint-vaksiner ved kontroll av parasittsykdom i forbindelse med tap av naturlig immunitet
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
DE60216958D1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
FR2818648B1 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326636

Country of ref document: EP